Sight Sciences (SGHT) Revenue & Revenue Breakdown
Sight Sciences Revenue Highlights
Latest Revenue (Y)
$81.06M
Latest Revenue (Q)
$21.37M
Main Segment (Y)
Surgical Glaucoma
Sight Sciences Revenue by Period
Sight Sciences Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $81.06M | 13.63% |
| 2022-12-31 | $71.33M | 45.70% |
| 2021-12-31 | $48.96M | 77.12% |
| 2020-12-31 | $27.64M | 18.38% |
| 2019-12-31 | $23.35M | 210.07% |
| 2018-12-31 | $7.53M | - |
Sight Sciences generated $81.06M in revenue during NA 2023, up 13.63% compared to the previous quarter, and up 1076.44% compared to the same period a year ago.
Sight Sciences Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $21.37M | 10.93% |
| 2024-03-31 | $19.27M | 2.74% |
| 2023-12-31 | $18.75M | -6.29% |
| 2023-09-30 | $20.01M | -14.75% |
| 2023-06-30 | $23.47M | 24.69% |
| 2023-03-31 | $18.82M | -8.37% |
| 2022-12-31 | $20.54M | 9.99% |
| 2022-09-30 | $18.68M | 8.40% |
| 2022-06-30 | $17.23M | 15.78% |
| 2022-03-31 | $14.88M | 1.33% |
| 2021-12-31 | $14.69M | 12.09% |
| 2021-09-30 | $13.10M | 4.52% |
| 2021-06-30 | $12.54M | 45.17% |
| 2021-03-31 | $8.63M | -3.96% |
| 2020-12-31 | $8.99M | 3.93% |
| 2020-09-30 | $8.65M | 147.03% |
| 2020-06-30 | $3.50M | -46.09% |
| 2020-03-31 | $6.50M | - |
Sight Sciences generated $21.37M in revenue during Q2 2024, up 10.93% compared to the previous quarter, and up 113.53% compared to the same period a year ago.
Sight Sciences Revenue Breakdown
Sight Sciences Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|
| Dry Eye | $6.75M | $5.74M | $2.46M |
| Surgical Glaucoma | $74.31M | $65.59M | $46.50M |
Sight Sciences's latest annual revenue breakdown by segment (product or service), as of Dec 23: Surgical Glaucoma (91.68%), and Dry Eye (8.32%).
Quarterly Revenue by Product
| Product/Service | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dry Eye | $1.13M | $1.01M | $2.54M | $1.58M | $1.14M | $1.49M | $1.79M | $1.60M | $1.33M | $1.01M | $762.00K | $655.00K | $547.00K |
| Surgical Glaucoma | $20.24M | $18.26M | $17.15M | $18.43M | $21.40M | $17.33M | $18.75M | $17.07M | $15.90M | $13.87M | $13.92M | $12.45M | $11.99M |
Sight Sciences's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: Surgical Glaucoma (94.73%), and Dry Eye (5.27%).
Sight Sciences Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| CNMD | CONMED | $1.24B | $332.10M |
| VREX | Varex Imaging | $893.40M | $209.10M |
| AVNS | Avanos Medical | $673.30M | $171.70M |
| AORT | Artivion | $354.00M | $98.02M |
| TCMD | Tactile Systems | $274.42M | $317.00K |
| FNA | Paragon 28 | $216.39M | $61.02M |
| ANIK | Anika Therapeutics | $166.66M | $41.92M |
| KIDS | OrthoPediatrics | $148.73M | $52.80M |
| SIBN | SI-BONE | $138.89M | $39.97M |
| SGHT | Sight Sciences | $81.06M | $21.37M |
| LUNG | Pulmonx | $68.67M | $20.78M |
| NPCE | NeuroPace | $65.42M | $18.12M |
| CVRX | CVRx | $39.30M | $11.81M |
| RPID | Rapid Micro Biosystems | $22.52M | $6.62M |
| OFIX | Orthofix Medical | $100.00K | $198.62M |
SGHT Revenue FAQ
What is Sight Sciences’s yearly revenue?
Sight Sciences's yearly revenue for 2023 was $81.06M, representing an increase of 13.63% compared to 2022. The company's yearly revenue for 2022 was $71.33M, representing an increase of 45.70% compared to 2021. SGHT's yearly revenue for 2021 was $48.96M, representing an increase of 77.12% compared to 2020.
What is Sight Sciences’s quarterly revenue?
Sight Sciences's quarterly revenue for Q2 2024 was $21.37M, a 10.93% increase from the previous quarter (Q1 2024), and a -8.95% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $19.26M, a 2.74% increase from the previous quarter (Q4 2023), and a 2.34% increase year-over-year (Q1 2023). SGHT's quarterly revenue for Q4 2023 was $18.75M, a -6.29% decrease from the previous quarter (Q3 2023), and a -8.72% decrease year-over-year (Q4 2022).
What is Sight Sciences’s revenue growth rate?
Sight Sciences's revenue growth rate for the last 3 years (2021-2023) was 65.57%, and for the last 5 years (2019-2023) was 247.16%.
What are Sight Sciences’s revenue streams?
Sight Sciences's revenue streams in c 23 are Dry Eye, and Surgical Glaucoma. Dry Eye generated $6.75M in revenue, accounting 8.32% of the company's total revenue, up 17.59% year-over-year. Surgical Glaucoma generated $74.31M in revenue, accounting 91.68% of the company's total revenue, up 13.29% year-over-year.
What is Sight Sciences’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Sight Sciences was Surgical Glaucoma. This segment made a revenue of $74.31M, representing 91.68% of the company's total revenue.